ArticleBMC plant biology2025
Combining transcriptomics and metabolomics to analyse the mechanism of allelopathy in Cyclachaena xanthiifolia.
Article in BMC plant biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Invasive plant species for sustainable security and agricultural biocontrol: integrating allelopathic essential oils and defensive barriers.Frontiers in plant science · 2026Pooled it
- Allelochemical signaling and phytohormone crosstalk in plants: molecular mechanisms and implications for sustainable weed management.Plant cell reports · 2026Review
- Multilevel synergistic mechanisms of a nanocarrier-enabled topramezone herbicide against invasive weeds.Journal of nanobiotechnology · 2026Article
- Evaluation of allelopathic potentialities of an invasive taxon, Mesosphaerum suaveolens (L.) Kuntze, and bio-assay-guided identification of the involved allelochemicals.Scientific reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
As a vicious invasive plant, Cyclachaena xanthiifolia has caused severe ecological disruption and significant reductions in crop yield, necessitating urgent control measures. However, the underlying mechanisms of its allelopathic invasion remain unclear, representing the primary bottleneck in current management strategies. In this study, we used metabolomic and transcriptomic analyses to evaluate the differences in allelopathy and related physiological and biochemical indices among different extract fractions of C.xanthiifolia, and to investigate how the allelopathy of C.xanthiifolia inhibits seed germination and seedling growth by altering metabolic pathways. GC-MS results identified several compounds with allelopathic potential, including fatty acids, terpenes, esters, alkanes, and aldehydes. Among them, n-butanol phase extract (NE) treatment significantly inhibited the germination and water absorption of mustard (Brassica juncea) seeds, changed the balance of the endogenous hormones abscisic acid (ABA) and gibberellins (GA) in seeds, destroyed the antioxidant enzyme system, and caused plasma membrane damage. Moreover, transcriptomic and broadly targeted metabolomic analyses showed that NE treatment interfered with primary metabolism, significantly enriched the carotenoid biosynthetic pathway, and led to a significant accumulation of ABA. The quantitative real-time PCR (qRT-PCR) results showed that the expression levels of 7 key genes involved in ABA biosynthesis and metabolic pathways were relatively high. The results showed that C.xanthiifolia may exert its allelopathic effects by disrupting the antioxidant enzyme system and interfering with primary metabolism and hormone signalling, and that the modulation of the ABA signalling pathway appears to play a key role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.